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Background: Compound 1-(4-chlorophenyl)-4,4,4-trifluoro-3-hydroxy-2-buten-1-one 22 
(compound 1) was identified as a hit against methicillin-resistant Staphylococcus aureus 23 
(MRSA-strain MW2).  24 
Methods and Results: The minimum inhibitory concentration (MIC) of compound 1 against 25 
MRSA was 4 µg/mL. The compound showed enhanced activity at acidic pH by lowering 26 
bacterial intracellular pH and, exhibited no lysis of human red blood cells (RBCs) at up-to 64 27 
µg/mL and its IC50 against HepG2 cells was 32 µg/mL. The compound reduced 1-log10 colony 28 
forming units of intracellular MRSA in macrophages and prolonged the survival of MRSA-29 
infected Caenorhabditis elegans (p=0.0015) and Galleria mellonella (p=0.0002).   30 
Conclusion: Compound 1 is a protonophore with potent in vitro and in vivo activity against 31 
MRSA and no mammalian cell toxicity up to 8 µg/mL that warrants further investigation as a 32 
novel antibacterial. 33 




Staphylococcus aureus, and especially methicillin resistant S. aureus (MRSA), is a prominent 36 
human pathogen [1] that causes skin, soft tissue, blood stream, heart valve, and prosthetic device 37 
infections [2, 3]. Staphylococcal drug resistance is mostly driven by antibiotic inactivating 38 
enzymes, such as β-lactamases, and/or alterations in antibiotic-binding proteins, such as 39 
penicillin binding proteins (PBPs) [2]. pH is an important environmental factor and stress-40 
inducer that plays a key role in bacterial growth [4]. S. aureus adapts to varying acidic 41 
conditions, such as those found on human skin and in biological fluids, including blood, saliva, 42 
and urine [4], and can survive the low intracellular pH (6.0 to 4.0) within phagocytizing cells or 43 
abscesses [5-8]. Bacterial adaptation and reduced activity of conventional antibiotics under 44 
acidic conditions have been reported to favor staphylococcal infections [9-11].  45 
Uncouplers, also known as protonophores, are compounds that dissipate proton 46 
(H+) gradients across lipid bilayers. Gradient dissipation is generally not mediated via channel 47 
proteins, but is instead driven by existing forces, such as membrane potential and pH gradients 48 
[12]. Niclosamide (used for tape worm infections) [13] and nitazoxanide (used for Giardia 49 
lamblia infections)  [14] are drugs that target proton motive force (PMF) and are used clinically 50 
to treat parasitic infections. Given the increasing threat of multi-drug resistant bacterial 51 
infections [15], novel agents targeting the PMF warrant investigation as a new antibacterial 52 
agents. 53 
(Z)-1-(4-Chlorophenyl)-4,4,4-trifluoro-3-hydroxy-2-buten-1-one (compound 1, Figure 1) 54 
was identified as a hit compound against MRSA in a Caenorhabditis elegans-MRSA high-55 
throughput screen [16] that is used to identify anti-MRSA compounds and simultaneously 56 
provide an indication of their toxicity to the host. Using C. elegans as a host is more cost-57 
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effective  than rodent models and takes advantage of the conserved innate immune system from 58 
nematodes to vertebrates [17].  We now report that compound 1 shows potent activity against 59 
MRSA in vitro and in the Galleria mellonella infection model, shows low mammalian cell 60 
cytotoxicity, and acts via a protonophoric mechanism, with activity increasing at acidic pH.  61 
Materials and Methods 62 
Compound Information. (Z)-1-(4-Chlorophenyl)-4,4,4-trifluoro-3-hydroxy-2-buten-1-one 63 
(Chembridge # 5404961, referred to herein as compound 1) was purchased from Chembridge 64 
(Chembridge Corporation, San Diego, CA, USA). The compound 1 is not soluble in water, hence 65 
the stock solutions of compound 1 were prepared by dissolving in DMSO (Sigma Aldrich, St. 66 
Louis, MO, USA) at 10 mg/mL and diluting as required for experiments.  67 
Bacterial and nematode stains. All bacteria were from the Mylonakis laboratory collection 68 
(Table 1). Strains were grown at 37°C. S. aureus (MRSA strain of MW2), Staphylococcus 69 
epidermidis and Enterococcus faecium strains were grown in tryptic soy broth (TSB) (BD 70 
Biosciences, Franklin Lakes, NJ, USA); Klebsiella pneumoniae, Acinetobacter baumannii, 71 
Pseudomonas aeruginosa and Enterobacter aerogenes were grown in Luria-Bertani broth (LB) 72 
(BD Biosciences). The C. elegans glp-4(bn2);sek-1(km4) double mutant strain was maintained at 73 
15°C on a lawn of Escherichia coli strain HB101 on 10 cm plates, as previously described [16]. 74 
The glp-4(bn2) mutation renders the strain unable to produce progeny at 25 °C [18] and the sek-75 
1(km4) mutation increases sensitivity to several pathogens [19], thereby reducing assay time. 76 
Antimicrobial susceptibility testing. In vitro antibiotic susceptibilities were measured using the 77 
broth microdilution and disc diffusion methods [20]. Broth microdilution assays were carried out 78 
in triplicate using Müller-Hinton broth (BD Biosciences) in 96-well plates (BD Biosciences) 79 
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with a total assay volume of 100 µL. Two-fold serial dilutions of compounds were prepared over 80 
the concentration range 0.01 ̶ 64 µg/mL. The initial bacterial inoculum was adjusted to OD600 = 81 
0.06 and assay solutions were incubated at 35°C for 18 hours. To determine the minimum 82 
inhibitory concentration (MIC), OD600 was measured after incubation and the lowest 83 
concentration of test compound that suppressed bacterial growth was reported as the MIC. Broth 84 
culture from the MIC assay (10 µL) was plated onto Müller-Hinton agar (BD Biosciences) and 85 
colony forming units (CFUs) were enumerated after overnight incubation at 37°C. The lowest 86 
concentration of compound that resulted in no colonies was reported as the minimal bactericidal 87 
concentration (MBC). 88 
Disk diffusion assays were performed on Müller-Hinton agar. Sterile blank disks (BD 89 
Biosciences) were impregnated with 25 µg of test compound and air-dried. Bacterial inoculum 90 
was spread over the plate and disks were placed on the agar surface. Antimicrobial susceptibility 91 
was determined by measuring the diameter of the zone of inhibition after incubating at 35°C for 92 
24 h. All experiments were performed in triplicate.  93 
Time to kill assays. MRSA-MW2 was used to probe the bacteriostatic/bactericidal properties of 94 
compound 1, as previously described [21]. Assays were carried out in duplicate in 10-mL tubes 95 
(BD Biosciences). Briefly, overnight cultures of MRSA-MW2 were diluted in fresh TSB to a 96 
density of 10
8
 cells/mL. Test compound at 4x MIC was added and the tubes were incubated at 97 
37°C with shaking. At periodic intervals, aliquots from each tube were serially diluted in TSB 98 
and plated onto tryptic soy agar (TSA, BD Biosciences). CFUs were enumerated after overnight 99 
incubation at 37°C. 100 
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Intracellular killing assays. RAW 264.7 macrophages were used to evaluate intracellular 101 
killing of MRSA-MW2 by compound 1. Assays were carried out in triplicate as described by 102 
Schmitt et al., [22]. Briefly, macrophages were cultured and maintained as described under 103 
mammalian cell cytotoxicity assays. Cells (50,000) were seeded in 24-well plates 24 h prior to 104 
infection. Multiplicity of infection (MOI) 25 (i.e. 25 bacterial cells per macrophage) of MRSA-105 
MW2 were added to macrophages for 2 h to promote phagocytosis. Planktonic bacteria were 106 
removed and DMEM containing 200 µg/mL gentamicin was added for 2 h to inhibit/kill 107 
remaining extracellular bacteria. Antibiotic and serum-free DMEM with or without compound 1 108 
was added and the cells incubated under 5% CO2 for 20 h. Macrophages were lysed by adding 109 
SDS to a final concentration of 0.02 % (i.e. lyses only macrophages and not ingested bacteria). 110 
Cell lysates were diluted serially and CFUs enumerated by plating on TSA plates. Vancomycin 111 
(8 µg/mL) was used as a positive control and DMSO at a final concentration of less than 0.1% as 112 
the negative control. 113 
Intracellular pH measurements. Intracellular pH measurements were performed in triplicate, 114 
as described by Marks et al. [23]. To summarize, MRSA-MW2 cells were washed with 115 
phosphate buffered saline (PBS, pH 7.4). AM-BCECF (membrane-permeable acetoxymethyl 116 
ester derivative of the dual-excitation ratiometric pH indicator dye BCECF; 2′,7′-bis-(2-117 
carboxyethyl)-5-(and-6)-carboxyfluorescein, Molecular Probes/ Thermo Fisher Scientific, ON, 118 
Canada, 25 µM) in DMSO was added to the cells and incubated for 30 min at 30°C. Cells were 119 
washed with PBS and added to PBS with or without compound 1 (10 µg/mL). The protonophore 120 
CCCP (carbonyl cyanide m-chlorophenyl hydrazone) (10 µg/mL) was used as a positive control. 121 
Calibration curves were obtained from cells suspended in PBS at varying pH over the range 122 
4.0 ̶9.0. 123 
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Bacterial membrane permeabilization assays. Sytox green (Life Technologies, Carlsbad, CA, 124 
USA) (a nucleic acid stain not permeable to intact membrane) was used to measure membrane 125 
permeabilization by test compounds, as previously described [24]. Assays were carried out in 126 
duplicate in 96-well plates (Corning, Corning, NY, USA) using MRSA-MW2. Bacteria were 127 
harvested from logarithmically growing cultures by centrifugation at 3724 x g for 5 minutes, 128 
washed twice with PBS (Gibco, Grand Island, NY, USA) and re-suspended in PBS to optical 129 
density OD595 = 0.5. Sytox green was added to a final concentration of 5 µM and cells were 130 
incubated in the dark for 30 min. Fifty microliters of cell suspensions were added to 50 µL of 131 
serially diluted test compound in PBS and the fluorescence intensity (excitation 485 nm; 132 
emission 530 nm) was measured at various time intervals using a Vmax microplate reader 133 
(Molecular Device Sunnyvale, CA, USA).  134 
Multi-step emergence of resistance. To generate mutants against the compound 1, MRSA-135 
MW2 was grown in MHB at OD600= 0.06 in the presence of serially diluted compound 1 and 136 
incubated overnight. From the highest drug concentration allowing visible growth at sub-MIC 137 
concentration, aliquots were used to dilute into fresh medium to inoculate the second set of serial 138 
drug dilutions as described by Dalhoff et al., [25]. After overnight incubation, bacteria were 139 
passaged sequentially for a period of 25 days. 140 
Human red blood cell hemolysis. Human erythrocytes (Rockland Immunochemicals, Limerick, 141 
PA, USA) were used to test the hemolytic properties of compound 1, as detailed in reference 142 
[26]. Briefly, 50 µL of 4% human erythrocytes suspended in PBS were added to 50 µL of test 143 
compound that had been serially diluted in PBS in 96 well plates. After incubating at 37°C for 1 144 
h, the plates were centrifuged at 500 x g for 5 min and 50 µL of supernatant from each well was 145 
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transferred to a second 96-well plate. Visual inspection and absorbance at 540 nm were used to 146 
measure hemolysis. 147 
Mammalian cell cytotoxicity assays. HepG2 cells were used to probe mammalian cell 148 
cytotoxicity of compound 1, as described by Kwon et al., [27]. Cells were grown in Dulbecco’s 149 
Modified Eagle Medium (DMEM) (Gibco) supplemented with 10% fetal bovine serum (FBS) 150 
(Gibco) and 1% penicillin/streptomycin (Gibco) and maintained at 37°C in 5% CO2. After 151 
harvesting and resuspension in DMEM, 100 µL of cells were added to wells of a 96-well plate at 152 
5 x 10
4
 cells/well. Compounds were serially diluted in serum and antibiotic-free DMEM, added 153 
to the monolayer and the plates incubated at 37°C in 5% CO2 for 24 h. At 4 h prior to the end of 154 
the incubation period, 10 µL of 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2, 4-disulfophenyl)-2H-155 
tetrazolium (WST-1) solution (Roche, Mannheim, Germany) was added to each well. WST-1 156 
reduction was monitored at 450 nm using a Vmax microplate reader. Assays were performed in 157 
triplicate and the percentage survival calculated by to DMSO-treated vehicle controls. 158 
Mutagenesis studies. The mutagenic properties of compound 1 were examined using the plate 159 
incorporation method with Salmonella typhimurium, as described in reference [28]. In brief, S. 160 
typhimurium strains TA 1535 and TA 1538 were purchased from American Type Culture 161 
Collection (ATCC, Manassas, VA, USA). Overnight culture of Salmonella strain (0.1 mL), 5 µL 162 
of compound 1 (10 µg, 20 µg, 30 µg and 40 µg per plate) or 5 µL of negative control or 5 µL of 163 
positive control and 0.5 mL of metabolic activation mix (S9, S-2067, Sigma) (final concentration 164 
of 5% S9) were added to sterile tubes. The mixture was incubated for 15 min, added to 2 mL of 165 
top molten agar containing traces of histidine/biotin. After gentle shaking the mixture was 166 
poured on the minimal glucose agar plates. Plates were incubated at 37°C for 24-48 h and 167 
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revertant colonies were counted. 4-Nitro-o-phenylenediamine (4-NOP) (20 µg/plate) was used as 168 
a positive control and DMSO as the negative control. 169 
C. elegans MRSA infection assay. The C. elegans-MRSA infection assay has been described 170 
previously [16]. In brief, adult sterile C. elegans glp-4(bn2);sek-1(km4) worms were grown at 171 
25°C and harvested with M9 buffer. MRSA-MW2 was grown overnight at 37°C in TSB under 172 
aerobic conditions and moved to anaerobic conditions at 37 °C. Bacteria were added to the wells 173 
of 384-well assay plates (Corning plate 3712) containing serially diluted test compound at a final 174 
OD600 of 0.04. Worms were added to each well using a Complex Object Parameter Analyzer and 175 
Sorter (COPAS, Union Biometrica, Holliston, MA, USA) and the plates incubated for 5 days at 176 
25 °C. Plated were washed to remove bacteria with a microplate washer and the worms stained 177 
with Sytox orange (Life Technologies, Carlsbad, CA, USA). After overnight incubation at 25°C, 178 
the plates were imaged using an Image Xpress Micro automated microscope (Molecular devices, 179 
Sunnyvale, CA, USA), capturing both transmitted light and TRITC channel (535 nm excitation, 180 
610 nm emission) fluorescent images with a 2X objective. Images were processed using the open 181 
source image analysis software CellProfiller (http://www.cellprofiller.org/). The ratio of Sytox 182 
worm area to bright field worm area for each well was converted to percentage survival by the 183 
software. Assays were completed in duplicate. 184 
Galleria mellonella MRSA infection assay. Twelve randomly selected Galleria mellonella 185 
larvae (Vanderhorst, Inc., St. Mary's, OH, USA) between 300-350 mg were used for each group 186 
in the experiment [29]. In brief, MRSA-MW2 cells were washed with PBS and diluted to 2x10
6
 187 
cells/mL, as determined by optical density at 600 nm, before inoculation into G. mellonella 188 
larvae. A 10 µL inoculum was injected into the last left proleg using a 10 µL Hamilton syringe. 189 
Compounds were administered at 25 µg/mL into the last right proleg before (prophylactic) or 2 h 190 
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after (therapeutic) inoculation and the moths incubated at 37°C. Three groups were used as 191 
controls: (1) injected with PBS only, (2) inoculated with MRSA-MW2 but treated with sham 192 
injections and (3) no manipulation. G. mellonella survival was evaluated up to 120 h, with larvae 193 
considered dead if unresponsive to touch. Killing curves and differences in survival were 194 
analyzed by the Kaplan-Meier method using GraphPad Prism version 6.04 (GraphPad Software, 195 
La Jolla, CA, USA). Statistical analysis (Kruskal-Wallis test) was carried out using the same 196 
program and p values of <0.05 were considered significant.   197 
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Results and Discussion 198 
Antimicrobial activity. We previously identified compound 1 as a hit compound that prolonged 199 
nematode survival in a throughput screening (HTS) assay using the C. elegans-MRSA infection 200 
model [16]. The compound treatments in the assay recorded Z scores of 34.7 and 18.2, 201 
respectively, where compounds producing scores greater than 3 were considered hits. In the 202 
current study the antibacterial activity of compound 1 was evaluated against a test panel of 203 
Gram-positive and Gram-negative pathogens. The compound was found to inhibit the growth of 204 
MRSA-MW2, S. epidermidis and E. faecium and one Gram-negative bacterium, Acinetobacter 205 
baumannii (Table 1). The MIC was 4 µg/mL for the three Gram-positives (c.f. vancomycin MIC 206 
= 4 µg/mL) and 32 µg/ mL for A. baumannii (polymyxin B MIC = 4 µg/mL). Three other Gram-207 
negative pathogens, Enterobacter aerogens, Klebsiella pneumoniae and Pseudomonas 208 
aeruginosa, showed no growth inhibition at 64 µg/mL compound 1. The MIC remained at ≤ 4 209 
µg/mL against 5 clinical isolates of MRSA strains and 5 methicillin-sensitive S. aureus (MSSA) 210 
strains (data not shown). The MBC of compound 1 was 16 µg/mL (i.e. 4x MIC) against MRSA-211 
MW2 and 8 µg/mL (2x MIC) for E. faecium (Table 1). In disk assays, the zone of inhibition 212 
around compound 1 was 25 mm for MRSA-MW2, and 21 mm for S. epidermidis strain 9142. 213 
For E. faecium and A. baumannii the zones were 21 mm and 10 mm, respectively (Table 1). 214 
Compound 1 is bacteriostatic against MRSA-MW2. “Time to kill” assays were carried out to 215 
evaluate whether compound 1 is bactericidal or bacteriostatic. When exposed to compound 1 at 216 
4x MIC (16 µg/mL), MRSA-MW2 cell CFU/mL counts were reduced by 1-log10 compared to 217 
the initial inoculum (Figure 2A), demonstrating that the compound is bacteriostatic. 218 
Killing of MRSA-MW2 inside macrophages. It is well established that S. aureus can survive as 219 
an intracellular pathogen [30]. In the next experiments, RAW 264.7 macrophages were exposed 220 
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to MRSA-MW2 cells and compound 1 at 8 µg/mL (2x MIC), vancomycin (8 µg/mL, 2x MIC) or 221 
DMSO control. It was found that compound 1 reduced intracellular bacteria by 1-log10 CFU/mL 222 
(Figure 2B), while vancomycin reduced nearly 1.5 log10 CFU/mL.  223 
Acidic pH enhances antibacterial activity of compound 1. Acidic environments can reduce 224 
the efficacy of some antibiotics, for example gentamicin, oxacillin, ciprofloxacin [11, 31]. S. 225 
aureus is able to tolerate a wide range of pH conditions (pH 5-9) and, importantly, 226 
staphylococcal infections in acidic environments, such as the skin, urinary tract and blood [10], 227 
can result in abscess formation and accumulation of pus [32] that ranges in pH between 6.0-7.3 228 
[6]. 229 
 The acidic character of compound 1, whose pKa (6.25, ref [33]) is close to physiological 230 
pH, led us to speculate that the compound may be eliciting antibacterial effects through a 231 
protonophoric mechanism [3]. To test this hypothesis, the MIC of compound 1 against MRSA 232 
MW2 was measured in media of varying pH alongside two antibiotics (vancomycin and 233 
gentamicin) that do not act as protonophores. At pH 7.0 all three compounds showed very 234 
similar activity (Figure 3C). At pH 6.0 the MIC of compound 1 was reduced 4-fold to 1 µg/mL 235 
and at pH 5.0 an 8-fold decrease was observed (MIC = 0.5 µg/mL) (Figure 3A-B). In contrast, 236 
the activity of the vancomycin and gentamicin decreased at lower pH, with MICs for both 237 
compounds rising to 8 µg/mL and 64 µg/mL at pH 6.0 and 5.0, respectively. These observations 238 
were consistent with previous studies showing that vancomycin and gentamicin are less active 239 
under acidic conditions [11]. Interestingly, at pH 8.0 the situation was reversed, with 240 
vancomycin and gentamicin showing improved potency (MIC = 1 µg/mL) and compound 1 241 
reduced activity (MIC = 8-16 µg/mL) (Figure 3D). 242 
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Effects of compound 1 on MRSA-MW2 intracellular pH and membrane proton gradients. 243 
Bacteria have the ability to maintain internal pH at or near neutral when the external pH is 244 
altered [34]. Dissipation of proton motive force (PMF) can lead to changes in internal pH, which 245 
has been shown to impair bacterial growth [34]. We hypothesized that if compound 1 is acting 246 
as a protonophore it should affect the S. aureus proton gradient, leading to intracellular pH 247 
changes. To evaluate this hypothesis, MRSA-MW2 cells were preloaded with the pH-sensitive 248 
fluorescent probe AM-BCECF and treated with compound 1. In the absence of compound the 249 
internal pH of MRSA-MW2 was measured at 7.5. After incubation for 30 min with compound 1 250 
the intracellular pH lowered to 6.5 (Figure 4A), consistent with the compound acting as a 251 
protonophore and dissipating the membrane PMF. To corroborate this finding, we tested the 252 
well-known protonophore carbonyl cyanide m-chlorophenylhydrazone (CCCP, pKa 5.95) [35-253 
37] and found that it too reduced intracellular pH of MRSA-MW2 cells to 6.5 after a 30 min 254 
incubation. Neither DMSO nor vancomycin treated cells showed any changes in intracellular pH. 255 
In addition, we performed permeabilization assays with the nucleic acid stain Sytox green, which 256 
is permeable only when membranes are damaged. No fluorescence was observed (Figure 4B) 257 
indicating that compound 1 did not cause damage to the bacterial cell membrane. As reported by 258 
Feng X et al., FDA-approved protonophoric drugs like niclosamide, nitazoxanide that dissipate 259 
the PMF [36], can be detected by changes in intracellular pH, supporting our observation that 260 
compound 1 acts as a protonophore. To characterize the exact mechanism of action (MOA), we 261 
passaged MRSA-MW2 in the presence of compound 1 to generate mutants but were unable to 262 
generate mutants after continuous passage for 25 days (data not shown).  263 
Mammalian cell cytotoxicity of compound 1. The US Food and Drug Administration (FDA) 264 
has previously approved drugs that target the PMF (e.g. niclosamide and clofazimine) for use as 265 
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anti-infectives [21, 36], in spite of their perceived toxicity. Since many antibiotics are delivered 266 
intravenously, we evaluated the toxicity of compound 1 towards human erythrocytes. Serial 267 
dilutions of the compound showed no hemolysis up to 64 µg/mL (Figure 5A). As many drugs 268 
are detoxified by the liver, we also evaluated compound 1 for cytotoxicity towards HepG2 liver 269 
cells [21]. The IC50 of compound 1 was found to be in the range 16-32 µg/mL (Figure 5B), or 270 
8-fold higher than the MIC observed in MRSA-MW2. 271 
Mutagenic properties of compound 1. The mutagenic properties of compound 1 were 272 
examined using a variation of the Ames test [28] that uses mutant Salmonella typhimurium 273 
strains that can be induced to revert from a histidine requirement back to the parental strain by 274 
mutagens [38]. Spontaneous revertant colonies observed with compound 1 at 40 µg, 30 µg, 20 275 
µg and 10 µg per plate were 4, 8, 22 and 34, respectively, for S. typhimurium strain TA 1535 and 276 
10, 18, 25 and 61 for strain TA 1538 (Table 2). The changes were similar to the carrier control 277 
and significantly less than those induced by the positive control mutagen 4-nitro-o-278 
phenylenediamine (4NOP). Taken together, these findings demonstrate that at concentrations 279 
close to MIC, compound 1 shows low mammalian cell toxicity and has no mutagenic properties. 280 
In vivo infection models. The nematode C. elegans serves as a simple whole animal host for 281 
examining the anti-infective properties and toxicity of small molecules [39]. The earlier high-282 
throughput screen using the C. elegans-MRSA model identified that compound 1 rescues 283 
nematodes from MRSA infection at the single concentration of 2.86 µg/mL (Figure 6A) [16]. 284 
The C. elegans-MRSA infection assay was repeated here using 2-fold serial dilutions of 285 
compound 1 from 0.5 to 64 µg/mL. The compound was confirmed to rescue C. elegans from 286 
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MRSA infection (p=0.0015) at concentrations (0.5 µg/mL) similar to vancomycin, which were 287 
below MIC (Figure 6B).  288 
In 2011, Desbois et al. reported a G. mellonella wax moth whole animal model for 289 
assessing compounds against S. aureus infections. The simple in vivo model provides a readout 290 
of compound efficacy and host toxicity and reduces the need for larger animal experiments [40]. 291 
The wax moth model has also been used to evaluate compounds [29] and phage therapies [41] 292 
against other pathogens. Compound 1 was tested in G. melonella larvae (n=12/group) both 293 
before (prophylactic) and after (therapeutic) inoculation with 2x10
6 
cells of MRSA-MW2. In 294 
both the prophylactic and therapeutic arms, survival of infected larvae was increased 295 
significantly (p=0.0002) in the presence of compound 1 (25 mg/kg) relative to vancomycin (25 296 
mg/kg) control (Figure 6C).  297 
Conclusion 298 
In summary, compound 1 shows bacteriostatic activity against MRSA that is enhanced at 299 
acidic pH. The compound is effective against intracellular MRSA and appears to act as a 300 
protonophore that dissipates the membrane proton gradient, resulting in decreased intracellular 301 
pH. Moreover, it demonstrated low cellular toxicity, is non-mutagenic and shows comparable 302 
activity to vancomycin in two whole animal alternative MRSA infection models. Based on these 303 
findings, compound 1 warrants further investigation as a novel antibacterial for treating MRSA 304 
infections.  305 
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Future perspective 306 
MRSA is categorized as a “serious threat” by the Centers for Disease Control and Prevention 307 
(CDC) and is associated with ≥11,000 deaths per year. Our study demonstrates that the 308 
compound 1-(4-chlorophenyl)-4,4,4-trifluoro-3-hydroxy-2-buten-1-one (compound 1) is active 309 
in vitro and in vivo against MRSA and appears to act through a protonophoric mechanism. In 310 
future work the compound should be advanced to vertebrate models and structural analogs 311 
prepared to probe structure-activity relationships, especially the relationship between pKa, 312 
potency/efficacy and toxicity.  313 
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Executive summary: 314 
• Compound 1-(4-chlorophenyl)-4,4,4-trifluoro-3-hydroxy-2-buten-1-one inhibited the 315 
growth of methicillin resistant Staphylococcus aureus with an MIC of 4.0 µg/ ml. 316 
• The compound is bacteriostatic.  317 
• Importantly, the efficiency of the compound was increased in acidic pH and the MIC was 318 
reduced by 4-fold (to 1 µg/ml) in pH 6.0 and by 8-fold (to 0.5 µg/ml) in pH 5.0.  319 
• Treatment with the compound resulted in a 1-log10 reduction of CFU/mL of intracellular 320 
MRSA-MW2 bacteria.  321 
• We confirmed the activity of the compound using two alternative model hosts: 322 
o In the C. elegans-MRSA infection model, treatment with the compound rescued 323 
C. elegans nematodes from S. aureus infection (p=0.0015). 324 
o In the G. mellonella model, the compound, administered before or after 325 
inoculation, resulted in prolonged survival (p=0.0002). 326 
•  Notably, administration of compound resulted in a reduced intracellular pH (6.5) of 327 
MRSA-MW2 by dissipating the proton gradient and concentrations up-to 64 µg/ml did 328 
not cause toxicity to human red blood cells. 329 
• This potential protonophore warrants further evaluation for the development of this 330 
compound as a novel antibacterial agent. 331 
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Table 1. Antibacterial activity of compound 1 (µg/mL)     
 compound 1 Vancomycin Polymyxin B 






4.0  16  4.0 16 64 >64 25  
Staphylococcus epidermidis 
9142 
4.0 16 4.0 16 64 >64 21  
Enterococcus faecium 
(ATCC E007) 
4.0  8  4.0 64 64 >64 21  
Acinetobacter baumanii 
(ATCC 17978) 
32 >64  >64 >64  4 8 10  
Enterobacter aerogens 
(EAE 2625) 
>64  >64  >64 >64  8 8 ND  
Klebsiella pneumoniae 
(ATCC 77326) 
>64 >64  >64 >64  8 8 ND  
Pseudomonas aeruginosa 
(PA 14) 
>64 >64  >64 >64  2 4 ND  




Table 2. Mutagenic properties of compound 1 determined by Ames test 
 







Salmonella typhi  
TA1535 
Salmonella typhi  
TA 1538 
DMSO 5.0 22 31 
compound 1 2.5 4 10 
 5.0 8 18 
 7.5 22 25 
 10.0 34 61 
4NOP 5.0 735 835 
  462 
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Figure Legends 463 
Figure 1. Structure of 1-(4-chlorophenyl)-4,4,4-trifluoro-3-hydroxy-2-buten-1-one 464 
(compound 1). 465 
Figure 2. In vitro killing of MRSA-MW2 cells by compound 1. A. Time to kill assays: 466 
MRSA-MW2 (108 cells/mL) were treated with DMSO or compound 1 (16 µg/mL, 4x MIC) or 467 
gentamicin (8 µg/mL, 4x MIC) and CFUs enumerated after incubating for various times. B. 468 
Killing of MRSA-MW2 in RAW 264.7 macrophages. Macrophages were exposed to MRSA-469 
MW2 cells (MOI = 25) for 2 h. Extracellular bacteria were killed by treatment with gentamicin 470 
(200 µg/mL) for 2 h and the macrophages exposed to 2x MIC compound 1 (8 µg/mL), 2x MIC 471 
vancomycin (8 µg/ mL) or DMSO control for 20 h. Cells were lysed and the bacteria plated and 472 
counted. Data represent the means ± SD (n=3). 473 
Figure 3. Effect of pH on antibacterial activity. The MICs of compound 1, vancomycin and 474 
gentamicin were measured against MRSA-MW2 at pH: (A) 5.0, (B) 6.0, (C) 7.0 and (D) 8.0. 475 
Data represent the mean ± SD (n=3). 476 
Figure 4. Intracellular pH and membrane permeability. A. S. aureus intracellular pH: 477 
MRSA-MW2 cells pre-loaded with the fluorescence pH indicator probe AM-BCECF were 478 
treated with 10 µg/ mL of compound 1, vancomycin, CCCP or DMSO (negative control) and 479 
fluorescence measurements taken. B. Membrane permeabilization by compound 1: MRSA-MW2 480 
cells were loaded with the membrane impermeable nucleic acid stain Sytox green and treated 481 
with compound 1 (3.125-50 µg/mL) and the fluorescence was measured at regular time interval 482 
post-treatment. Data represent the mean ± SD (n=3). 483 
28 
 
Figure 5. Hemolysis and cytotoxicity assays. A. Hemolytic activity of compound 1: Human 484 
erythrocytes were treated with various concentrations of compound 1 (0.06-64 µg/mL) or Triton 485 
X (0.001 to 1.0 %) for 1 h and the supernatant was examined for hemolysis. B. Cytotoxicity of 486 
compound 1 in HepG2 cells: HepG2 cells were treated with increasing concentrations compound 487 
1 (0.125-64 µg/mL) and incubated for 24, 48 or 72 h. Data represent the mean ± SD (n=3).  488 
Figure 6. Whole animal S. aureus infection models. A. Bright field and Sytox orange stained 489 
images of MRSA-MW2 -infected C. elegans in the presence of DMSO (1%), compound 1 (2.86 490 
µg/mL) or vancomycin (10 µg/mL).  Images were obtained from the original HTS campaign. B. 491 
Rescue of C. elegans nematodes infected with MRSA MW2 by compound 1 over the 492 
concentration range 0.5-64 µg/mL. Data represent the mean ± SD (n=15). C. G. mellonella 493 
survival assay: Compound 1 (25 mg/kg) were administrated into the last right proleg before 494 
(prophylactic) or after (therapeutic) bacterial inoculation (2 x 10
6
 cells/mL). Vancomycin (25 495 
mg/kg) and DMSO or no injection were used as positive and negative controls, respectively.  496 
  497 
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Figure 1.  498 
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Figure 2.  500 
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Figure 4.  505 


















































































































  509 
34 
 
Figure 6.  510 
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